Bacterial vesicles for radiotherapeutic delivery of boron

Conjugating fluorescent boron with bacterial vesicles and bispecific antibodies addresses the limitations of existing boron delivery agents, achieving selective tumor cell delivery and optimized radiotherapy dosing for enhanced therapeutic efficacy.

WO2026133273A1PCT designated stage Publication Date: 2026-06-25ENGENEIC MOLECULAR DELIVERY PTY LTD
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
ENGENEIC MOLECULAR DELIVERY PTY LTD
Filing Date
2025-12-19
Publication Date
2026-06-25

AI Technical Summary

Technical Problem

Existing boron delivery agents for radiotherapy, such as BPA and BSH, fail to meet criteria of low intrinsic toxicity, selective tumor cell delivery, rapid clearance, and metabolic stability, limiting their effectiveness in boron neutron capture therapy (BNCT) and proton boron capture therapy (PBCT).

Method used

Conjugating a fluorescent moiety with boron-containing compounds to form fluorescent boron, which is then encapsulated in bacterial vesicles and coated with a bispecific antibody for targeted delivery to tumor cells, enabling neutron-capture and proton-fusion therapies.

Benefits of technology

The approach allows for selective delivery of boron to tumor cells, enhancing therapeutic efficacy with minimal damage to normal cells, and enables precise determination of boron uptake and distribution for optimized radiotherapy dosing.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure IB2025063238_25062026_PF_FP_ABST
    Figure IB2025063238_25062026_PF_FP_ABST
Patent Text Reader

Abstract

Intact bacterial vesicles are highly effective for in vivo delivery of boron for radiotherapeutic purposes, as in boron neutron capture therapy. A compound comprising a boron isotope, such as boron-10 or boron-11, can be joined chemically to a fluorescent moiety to produce a molecule that can be loaded stably into bacterial vesicles, which when coated with an appropriately targeting bispecific antibody can deliver boron specifically into tumor cells in an amount enabling boron-mediated radiotherapy that eliminates tumor cells with minimal damage to adjacent normal cells.
Need to check novelty before this filing date? Find Prior Art